Immunome Research
Open Access

Convergence of Immunology and Synthetic Biology in Modern Healthcare

Matthew Brown^{* *}Correspondence: Matthew Brown, Department of Immunology, Northwestern University Feinberg School of Medicine, Chicago, USA, Email:

Author info »

Description

Synthetic immunology is an emerging interdisciplinary field that merges principles from synthetic biology and immunology to design and engineer immune cells and immune responses. It seeks to create customizable immune systems that can be precisely programmed to fight diseases, address immune deficiencies, and regulate immune responses [1-4]. The field holds the potential advances in therapeutic interventions for diseases ranging from cancer to autoimmune disorders. By leveraging technologies like gene editing, cellular reprogramming, and computational modelling, synthetic immunology is the way for the next generation of medical treatments.

Foundations of synthetic immunology

Synthetic immunology builds on synthetic biology's core principles, which aim to design and engineer biological systems for specific, predetermined functions [5]. The immune system, with its complexity and adaptability, presents an ideal target for such engineering. The foundation of synthetic immunology rests on several key technological pillars:

Gene editing technologies: clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and other gene-editing tools are at the heart of synthetic immunology. They allow researchers to precisely modify immune cells, adding new functionalities or enhancing existing ones.

Synthetic biology circuits: Immune cells can be reprogrammed using synthetic biological circuits—engineered networks of genes, proteins, and signaling pathways that control cellular behavior.

Cellular reprogramming: Cellular reprogramming techniques, which involve transforming cells into different types, are being used to convert non-immune cells into immune cells. This technology is particularly useful in generating specific types of immune cells, such as T cells or macrophages that are difficult to obtain from patients.

Applications of synthetic immunology

The potential applications of synthetic immunology are vast and can revolutionize multiple areas of medicine. Some key applications include:

Cancer immunotherapy: Synthetic immunology is having a profound impact on cancer treatment, particularly through the development of Chimeric Antigen Receptor (CAR) T cells therapies. CAR T cells are T cells that have been genetically engineered to express receptors specific to cancer cells. These cells are reintroduced into the patient’s body, where they seek out and destroy tumour cells [6].

Autoimmune disease treatment: Synthetic immunology also hold potential. for treating autoimmune diseases, where the immune system mistakenly attacks the body’s tissues.

Infectious disease vaccines: Synthetic immunology is revolutionizing vaccine design. Traditional vaccines rely on introducing attenuated or inactive pathogens to the immune system [7].

Organ transplantation: One of the challenges in organ transplantation is the risk of the recipient's immune system rejecting the donor organ.

Allergy treatments: Researchers are also exploring how synthetic immunology can be used to treat allergies. By engineering immune cells to ignore allergens or modulate the body’s allergic response, synthetic immunology offers the potential for longterm solutions to allergies.

Challenges and ethical considerations

While synthetic immunology has a great deal of potential, it also presents significant challenges and ethical concerns. Some of the key challenges include:

Off-target effects: Gene editing technologies, like CRISPR, may cause unintended modifications in the genome, potentially leading to harmful mutations [8,9]. Developing more accurate and precise gene-editing tools is essential for minimizing these risks.

Immune system complexity: The immune system is highly complex and context-dependent, and reprogramming immune cells can have unpredictable effects.

Ethical considerations: The ability to modify the immune system raises ethical concerns, particularly in the context of human enhancement and germline editing.

Future directions

Synthetic immunology is still in its early stages, but its future potential is immense. Advances in computational biology, machine learning, and artificial intelligence will play an increasingly important role in designing and optimizing synthetic immune systems. Machine learning algorithms can analyses large datasets of immune responses and predict how engineered immune cells will behave in different conditions, accelerating the development of new therapies [10].

Another potential avenue for synthetic immunology is personalized medicine. As we continue to improve our understanding of individual genetic and immune profiles, synthetic immunology can be specific to create personalized therapies.

Conclusion

Synthetic immunology represents a revolutionary approach to medicine, with the potential to transform the treatment of cancer, autoimmune disorders, infectious diseases, and more. By combining advances in gene editing, cellular reprogramming, and synthetic biology, researchers are creating immune cells that can be precisely programmed to perform specific tasks. While challenges and ethical considerations remain, synthetic immunology is poised to become a cornerstone of 21st century medicine, giving assume for more effective treatments and cures for a wide range of diseases.

References

1. Geering B, Fussenegger M. Synthetic immunology: Modulating the human immune system. Trends Biotechnol. 2015;33(2):65-79.

   [Crossref] [Google Scholar] [PubMed].

2. Liu A.P, Appel E.A, Ashby P.D. The living interface between syntheticbiology and biomaterial design Nat. Mater. 2022;21(4):390-397.

   [Crossref] [Google Scholar] [PubMed].

3. Hobom, B. Gene surgery: on the threshold of synthetic biology. Med Klin. 1980;75(24):834-841.

   [Google Scholar] [PubMed].

4. Bai P, Ye H, Xie M, Saxena P, Zulewski H, Charpin-El Hamri G, et al. A synthetic biology-based device prevents liver injury in mice. J Hepatol. 2016;65(1):84-94.

   [Crossref] [Google Scholar] [PubMed].

5. Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145-161.

   [Crossref] [Google Scholar] [PubMed].

6. Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev. Clin Oncol. 2023;20(1):49-62.

   [Crossref] [Google Scholar] [PubMed].

7. Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: Bright future or dark reality?. Mol Ther. 2020;28:2320-2339.

   [Crossref] [Google Scholar] [PubMed].

8. Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.

   [Crossref] [Google Scholar] [PubMed].

9. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-13555.

   [Crossref] [Google Scholar] [PubMed].

10. Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18(9):558-576.

    [Crossref] [Google Scholar] [PubMed].